PASI improvement in the first 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE guselkumab clinical trials

被引：0
|
作者：
Papp, Kim [1 ,2 ]
Vender, Ronald [3 ]
Langley, Richard [4 ]
Ho, Vincent [5 ]
Park-Wyllie, Laura [6 ]
Abbarin, Nastaran [6 ]
Miller, Megan [7 ]
You, Yin [7 ]
Yang, Ya-Wen [8 ]
机构：
[1] Probity Med Res Inc, Waterloo, ON, Canada
[2] K Papp Clin Res, Waterloo, ON, Canada
[3] McMaster Univ, Div Dermatol, Dept Med, Hamilton, ON, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada
[6] Janssen Inc, Janssen Med Affairs, Toronto, ON, Canada
[7] Janssen Res & Dev LLC, Spring House, PA USA
[8] Janssen Pharmaceut Companies Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB203 / AB203
页数：1
相关论文
共 50 条
  • [1] Clinical response after guselkumab treatment among adalimumab PASI 90 nonresponders: Results from the VOYAGE 1 and 2 trials
    Griffiths, Christopher E. M.
    Radtke, Marc Alexander
    Youn, Sang Woong
    Bissonnette, Robert
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    You, Yin
    Shen, Yaung-Kaung
    Strober, Bruce
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB78 - AB78
  • [2] CLINICAL RESPONSE AFTER GUSELKUMAB TREATMENT AMONG ADALIMUMAB PASI 90 NON-RESPONDERS: RESULTS FROM THE VOYAGE 1 AND 2 TRIALS
    Griffith, Christopher
    Radtke, Marc Alexander
    Youn, Sang Woong
    Bissonnette, Robert
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    You, Yin
    Shen, Yaung-Kaung
    Strober, Bruce
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 20 - 20
  • [3] Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
    Reich, Kristian
    Griffiths, Christopher E. M.
    Gordon, Kenneth B.
    Papp, Kim A.
    Song, Michael
    Randazzo, Bruce
    Li, Shu
    Shen, Yaung-Kaung
    Han, Chenglong
    Kimball, Alexa B.
    Armstrong, April W.
    Foley, Peter
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 936 - 945
  • [4] Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Thaci, Diamant
    Papp, Kim A.
    Ho, Vincent
    Ghoreschi, Kamran
    Kim, Byung Soo
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Chan, Daphne
    Yu, Jenny
    Yang, Ya-Wen
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Crowley, Jeffrey
    Foley, Peter
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (01) : 132 - 134
  • [5] Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment
    Blauvelt, Andrew
    Gordon, Kenneth B.
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Foley, Peter
    Song, Michael
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Ramachandran, Paraneedharan
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB174 - AB174
  • [6] Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
    Reich, Kristian
    Strober, Bruce
    Langley, Richard
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Foley, Peter
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [7] Mean neutrophil-to-lymphocyte ratio improves over time with guselkumab treatment vs. placebo in the VOYAGE 1 and VOYAGE 2 clinical trials
    Kirby, Brian
    Kearney, Niamh
    Gorecki, Patricia
    Buyze, Jozefien
    Yang, Ya-Wen
    Merola, Joseph
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB193 - AB193
  • [8] Consistency of response (PASI 90 or 100 and IGA 0 or 0/1) in patients with moderate to severe psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials
    Gordon, Kenneth
    Menter, Alan
    Ferris, Laura
    Martorell, Antonio
    Kim, Byung Soo
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB87 - AB87
  • [9] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
    Blauvelt, Andrew
    Tsai, Tsen-Fang
    Langley, Richard G.
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Yang, Ya-Wen
    Papp, Kim A.
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 827 - 834
  • [10] Safety of guselkumab in patients with plaque psoriasis through 2 years: a pooled analysis from VOYAGE 1 and VOYAGE 2
    Reich, K.
    Papp, K.
    Armstrong, A. W.
    Wasfi, Y.
    Jiang, G.
    Shen, Y-K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E297 - E297
12345